Cluster of Severe Arginase 1 Deficiency in the Comoros: Clinical, Neuroimaging, and Molecular Features in 17 Patients From Mayotte Compared With 10 From Paris

科摩罗群岛严重精氨酸酶1缺乏症聚集性病例:马约特岛17例患者与巴黎10例患者的临床、神经影像学和分子特征比较

阅读:2

Abstract

Arginase 1 deficiency (ARG1D) is the least common urea cycle disorder. Neonatal onset is rarely described, and hyperammonemic coma is less common in patients with ARG1D compared to other urea cycle disorders. In recent years, we diagnosed a high number of ARG1D patients in Mayotte, an insular (Comoro Islands) department of France. This study aimed at retrospectively analyze and compare our patients' data with those diagnosed and followed in Paris. We present a series of 27 subjects included either in the Center Hospitalier de Mayotte (CHM), Mamoudzou, France (n = 17), or in Hôpital Necker-Enfants Malades (NEM), Paris, France (n = 10). Median age at diagnosis (n = 27) was 2 years (ranging from birth to 15 years). Patients diagnosed at CHM were generally older than those diagnosed at NEM, which may reflect a longer diagnostic delay in CHM. The main clinical features at diagnosis included hyperammonemic coma (with or without liver failure) and neurodevelopmental delay with spastic diplegia. Brain MRI could be either normal or showed severe lesions in patients with overt hyperammonemia at diagnosis. Eight different ARG1 variants were identified, including two variants (c.466-2 A>G and c.766G>A) that were found exclusively in subjects originating from the Comoro Islands. Despite no significant differences in laboratory parameters, clinical outcomes remained better in NEM versus CHM possibly ascribable to a longer diagnostic delay in CHM. These findings revealed a new cluster of ARG1D associated with two severe variants in Mayotte, suggesting that this region could possibly benefit from targeted newborn screening for ARG1D due to its overrepresentation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。